Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-21479 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- IL12RB2 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Recombinant protein fragment
- Description
- Recommended positive controls: 293T, A431, H1299, HeLaS3, HepG2, Molt-4, Raji.
- Concentration
- 1 mg/mL
Submitted references A short deletion in the DNA-binding domain of STAT3 suppresses growth and progression of colon cancer cells.
Xiong YJ, Liu DY, Shen RR, Xiong Y
Aging 2021 Feb 1;13(4):5185-5196
Aging 2021 Feb 1;13(4):5185-5196
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot using IL12RB2 Polyclonal Antibody (Product # PA5-21479). Sample (30 µg whole cell lysate). A: A431. B: HepG2. 7.5% SDS PAGE. IL12RB2 Polyclonal Antibody (Product # PA5-21479) diluted at 1:5,000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 3 STAT3 del reduces in vitro growth, survival and migration of colon cancer cells. ( A ) CCK8 assay results show the proliferation rate of SW480, SW620 and HCT-116 cells with wild type STAT3 or STAT3 del . ( B ) TUNEL assay results show the apoptotic rate of SW480, SW620 and HCT-116 cells with wild type STAT3 or STAT3 del . ( C ) Wound healing assay results show the migration rate of SW480, SW620 and HCT-116 cells with wild type STAT3 or STAT3 del . * denotes p